Dupixent

Active Ingredient(s): Dupilumab
FDA Approved: * March 28, 2017
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Dupixent Overview

Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases such as eczema.[1][2] Side effects include allergic reactions, cold sores, and inflammation of the cornea.[2] It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme.[3][4] The US Food and Drug Administration has designated dupilumab a “breakthrough therapy” which is designed to speed promising new drugs to market.[5] It received FDA approval in 2017.[2] As of 2017 it costs about 37,000 USD p...

Read more Dupixent Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dupilumab

Recent Dupixent Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dupilumab
  • Injection: 150mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dupixent: (1 result)

Sorted by National Drug Code
  • 0024-5914 Dupixent 300 mg/2ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Dupilumab or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 20 August 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.